 
                                UNITE4TB
@unite4tb
Our goal is to deliver novel phase 2 clinical trials that will accelerate the development of new TB drugs and regimens.
ID: 1501202408084545538
http://www.unite4tb.org 08-03-2022 14:25:45
282 Tweet
626 Takipçi
192 Takip Edilen
 
        Our panel discussion on equitable #access to UNITE4TB innovations in action with Francesca Conradie (World Health Organization (WHO) ), Marco Cavaleri (EU Medicines Agency), Ariane McCabe (GSK ), Eugene Sun (TB Alliance), Fuad Mirzayev (World Health Organization (WHO) ), Brian Kaiser (GDF). Moderation by Jonathan Servello (Università degli Studi di Milano).
 
                        
                    
                    
                    
                 
         
        Day 2 of the UNITE4TB Annual Meeting begins with a talk by Tek-Ang Lim (Scientific Officer, Innovative Health Initiative) on our Interim Review. We also hear from our Scientific, Ethics, and Community Advisory Board members and our Young Investigators Group. IMI AMR ACCELERATOR EFPIA DZIF (inaktiv)
 
                        
                    
                    
                    
                 
        “Trial site engagement is crucial. Being people-centered means offering options, not deciding for others. Let's put decision-making into the hands of the people," said Blessina Kumar of our Community Advisory Group, speaking at our Annual Meeting, together with Paul Sommerfeld.
 
                        
                    
                    
                    
                 
        An insightful panel discussion about the UNITE4TB Young Investigators Group on how best to involve young researchers in the Consortium. Innovative Health Initiative IMI AMR ACCELERATOR
 
                        
                    
                    
                    
                 
        That’s a wrap for the 2024 UNITE4TB Annual Meeting, kindly hosted by our Consortium Partner Uppsala universitet. Funded by Innovative Health Initiative. Proud partner of the IMI AMR ACCELERATOR #YesWeCanEndTB #PublicPrivatePartnership
 
                        
                    
                    
                    
                 
        #JustOut! New World Health Organization (WHO) guidance on #TB surveillance. This is crucial for all countries to track the #TB epidemic &monitor quality, coverage &effectiveness of TB prevention & care services in a consistent & standardized way, aligned with #EndTB commitments. createsend.com/t/d-F18490C7D6…
 
        This might be interesting for you! ERA4TB Project UNITE4TB Global Antibiotic R&D Partnership (GARDP)
 
        📢Happening soon! UNITE4TB #webinar: Expert interview: an approach to market-shaping and access to #TB medicines Date: 27 June, 13:00–14:00 CEST Register here👉ersnet.org/events/expert-… Innovative Health Initiative ISPUP ERS IMI AMR ACCELERATOR
 
         
        The fight against #TB & #AntimicrobialResistance needs urgent action! Sustainable investment is key! We join our fellow IMI AMR ACCELERATOR partners in this call to action 👉 unite4tb.org/newsroom/susta… #AMR #GlobalHealth #UNGAHLM Innovative Health Initiative EFPIA Nature Reviews Drug Discovery
 
                        
                    
                    
                    
                 
         
        Managing adverse events in TB care is key to treatment success! Insights from our 11th #UNITE4TB webinar covered strategies to improve safety and treatment adherence. Learn more 👉 unite4tb.org/newsroom/manag… Simon Tiberi GSK Innovative Health Initiative IMI AMR ACCELERATOR
 
                        
                    
                    
                    
                 
        Heading to #UnionConf? Join the #PANTB Collaboration & UNITE4TB on 14 November to gain insight into the challenges & solutions shaping #TB drug development. Also hear an exclusive update on the PAN-TB trial. #EndTB More info: bit.ly/3NF1C0A The Union Conference Innovative Health Initiative
 
                        
                    
                    
                    
                 
         
                         
                        